Shares of GT Biopharma, Inc. (GTBP) have been struggling lately and have lost 12% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the ...

Shares of GT Biopharma, Inc. (GTBP) have been struggling lately and have lost 5.3% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean ...

GT Biopharma, Inc. (GTBP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating ...

GT Biopharma (NASDAQ:GTBP) shares rose Tuesday morning before pulling back and turning negative after the company announced a direct offering. The Details: GT Biopharma entered into a definitive ...

Shares of GT Biopharma, Inc. (GTBP) have been struggling lately and have lost 6.6% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

Fintel reports that on August 7, 2023, EF Hutton reiterated coverage of GT Biopharma (NASDAQ:GTBP) with a Hold recommendation. As of August 2, 2023, the average one-year price target for GT Biopharma ...

GT Biopharma, Inc. (GTBP) stock price is 0.47 and GT Biopharma, Inc. (GTBP) 10-day simple moving average is 0.46. GT Biopharma, Inc. (GTBP) stock price is 0.47 and GT Biopharma, Inc. (GTBP) 50-day ...

Clinical-stage immuno-oncology company GT Biopharma Inc. (NASDAQ:GTBP) announced on Wednesday that enrollment in the dose escalation cohorts of the Phase 1 trial of GTB-3650 for relapsed or refractory ...